Cadence Neuroscience has filed a notice of an exempt offering of securities to raise $26,029,994.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Cadence Neuroscience is raising $26,029,994.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Kent Leyde played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Cadence Neuroscience
Cadence Neuroscience is developing a fundamentally new approach to neuromodulation. Our system has the ability to detect specific signals from the brain and deliver electrical stimulation to modify the activity of neural circuits. Based on pioneering research performed at Mayo Clinic, our technology provides a personalized approach with unprecedented potential to treat many neurological diseases that cannot be adequately addressed with available treatment options. Cadence aims to relieve suffering for many people, starting with those with epilepsy. Our technology has demonstrated breakthrough results and is currently being evaluated in clinical trials.
To learn more about Cadence Neuroscience, visit http://www.cadenceneuro.com/
Contact:
Kent Leyde, President and Chief Executive Officer
425-681-6863
https://www.linkedin.com/in/kent-leyde-2342a45/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.